GW Pharma Wants Out Of Canopy's CBD Patent Dispute

By Sarah Jarvis (March 8, 2021, 4:11 PM EST) -- GW Pharmaceuticals has asked a Texas federal court to toss a patent suit brought by Canadian cannabis company Canopy Growth over the flagship CBD drug Epidiolex, arguing that the court has no jurisdiction because the pharmaceutical company does not have enough of a presence in Texas.

GW said in a motion to dismiss on Friday that it is organized under the laws of England and Wales with a primary place of business in Cambridge, that it has no physical presence in the Lone Star State and that it is not registered to do business there.

"Contrary to Canopy's assertions, GW PLC...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!